nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics
|
Hong, Enping |
|
2019 |
141 |
C |
p. 3-22 |
artikel |
2 |
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
|
Hutmacher, Cornelia |
|
2019 |
141 |
C |
p. 67-91 |
artikel |
3 |
CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs
|
Rahbarizadeh, F. |
|
2019 |
141 |
C |
p. 41-46 |
artikel |
4 |
Editorial Board
|
|
|
2019 |
141 |
C |
p. ii |
artikel |
5 |
Engineering lymphocytes with RNAi
|
Ramishetti, Srinivas |
|
2019 |
141 |
C |
p. 55-66 |
artikel |
6 |
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
|
Margolis, Naama |
|
2019 |
141 |
C |
p. 104-124 |
artikel |
7 |
Reprogramming the lymphocyte axis for advanced immunotherapy
|
Moghimi, S. Moein |
|
2019 |
141 |
C |
p. 1-2 |
artikel |
8 |
Synthetic T cell receptor-based lymphocytes for cancer therapy
|
Getts, Daniel |
|
2019 |
141 |
C |
p. 47-54 |
artikel |
9 |
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
|
Karnell, Jodi L. |
|
2019 |
141 |
C |
p. 92-103 |
artikel |
10 |
T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer
|
Eisenberg, Vasyl |
|
2019 |
141 |
C |
p. 23-40 |
artikel |